Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors

Sara Manglaviti,Marta Bini,Giulia Apollonio,Ernesto Zecca,Giulia Galli,Sabina Sangaletti,Alice Labianca,Elisa Sottotetti,Marta Brambilla,Mario Occhipinti,Claudia Proto,Arsela Prelaj,Diego Signorelli,Alessandro De Toma,Giuseppe Viscardi,Teresa Beninato,Laura Mazzeo,Achille Bottiglieri,Rita Leporati,Giuseppe Fotia

Lung Cancer（2023）

Cited 0|Views40
No score
Abstract
•Impact of bone tumor burden on survival upon bone targeted agents in aNSCLC pts treated with ICI is still unknown.•Our findings highlight a survival benefit in aNSCLC pts with HBTB treated with concomitant ICI and BTA, especially denosumab.•HBTB should be included as a stratification factor in future trials assessing BTA and ICI combinations inaNSCLC pts with BM.
More
Translated text
Key words
high bone tumor burden,immune checkpoint inhibitors,cell lung cancer,lung cancer,checkpoint inhibitors,non-small
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined